In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen ...

An AI model significantly improved recurrence risk stratification vs. recurrence score among patients with hormone ...

MammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer. High-risk patients benefit significantly from chemotherapy, while low-risk ...

Adjuvant radiation and endocrine therapy significantly reduce locoregional recurrence in early-stage breast cancer post-lumpectomy, especially in low-risk patients. Radiation therapy notably decreases ...

LONDON, Dec 10 (Reuters) - Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, in what it said ...

Researchers have developed a genomic model that could improve predictions of long-term recurrence in a common form of breast ...

New data means the drug, Kisqali, could be used in a broader range of patients. A breast cancer drug already on the market has been found to lower the chances of breast cancer recurring, an ...

Please provide your email address to receive an email when new articles are posted on . Women who breastfed after breast cancer did not have an increased risk for recurrence or contralateral disease.